Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
July 14 2017 - 7:30AM
Business Wire
Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s
disease programs at the Alzheimer's Association International
Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.
The planned poster presentations include:
- Change from Baseline in Clinical
Dementia Rating Scale Cognitive and Functional Domains in PRIME, a
Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal
Antibody Aducanumab (BIIB037). Poster 1-053: July 16, 2017, 9:30
a.m. GMT+1. This new post-hoc analysis shows the change in the
cognitive and functional subscores, which are derived from the
previously reported clinical dementia rating (CDR) score for the
overall and early Alzheimer’s disease populations in the 1, 3, 6
and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b.This
poster will be available concurrently with the session on the
Investors section of the Biogen company website,
www.Biogen.com.
- Signs and Symptoms of Alzheimer’s
Disease Noted in Health Records up to 5 Years Prior to
Diagnosis. Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1.
This analysis reports the documentation of cognitive and behavioral
impairment from U.S. medical health records, prior to an
Alzheimer’s disease diagnosis.
About Aducanumab
Aducanumab (BIIB037) is an investigational compound being
developed for the treatment of early Alzheimer’s disease.
Aducanumab is a human recombinant monoclonal antibody (mAb) derived
from a de-identified library of B cells collected from healthy
elderly subjects with no signs of cognitive impairment or
cognitively impaired elderly subjects with unusually slow cognitive
decline using Neurimmune’s technology platform called Reverse
Translational Medicine (RTM). Biogen licensed aducanumab from
Neurimmune under a collaborative development and license
agreement.
About Biogen
Through cutting-edge science and medicine, Biogen discovers,
develops and delivers worldwide innovative therapies for people
living with serious neurological and neurodegenerative diseases.
Founded in 1978, Biogen is a pioneer in biotechnology, and today
the company has the leading portfolio of medicines to treat
multiple sclerosis; has introduced the first and only approved
treatment for spinal muscular atrophy; and is at the forefront of
neurology research for conditions including Alzheimer’s disease,
Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also
manufactures and commercializes biosimilars of advanced biologics.
For more information, please visit www.biogen.com. Follow us on
social media – Twitter, LinkedIn, Facebook and YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements,
including statements relating to the development and potential
benefits, safety and efficacy of investigational drugs, including
aducanumab and results of certain clinical studies. These
statements may be identified by words such as “believe,” “except,”
“may,” “plan,” “potential,” “will” and similar expressions, and are
based on our current beliefs and expectations. You should not place
undue reliance on these statements or the scientific data
presented. Drug development and commercialization involve a high
degree of risk, and only a small number of research and development
programs result in commercialization of a product. Results in early
stage clinical trials may not be indicative of full results or
results from later stage or larger scale clinical trials and do not
ensure regulatory approval. Factors which could cause actual
results to differ materially from our current expectations include
the risk that we may not fully enroll our clinical trials or
enrollment will take longer than expected, unexpected concerns may
arise from additional data or analysis, including data, analysis or
results obtained during our clinical trials, regulatory authorities
may require additional information or further studies, or may fail
to approve or may delay approval of our drug candidates, or we may
encounter other unexpected hurdles which may be impacted by, among
other things, the occurrence of adverse safety events, failure to
obtain regulatory approvals in certain jurisdictions, failure to
protect intellectual property and other proprietary rights, product
liability claims, third party collaboration risks, and the other
risks and uncertainties that are described in the Risk Factors
section of Biogen’s most recent annual or quarterly report and in
other reports Biogen has filed with the U.S. Securities and
Exchange Commission. Any forward-looking statements speak only as
of the date of this press release and we assume no obligation to
update any forward-looking statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170714005205/en/
BiogenMEDIA CONTACT:Catherine Falcetti, +1
781-464-3260public.affairs@biogen.comorINVESTOR CONTACT:Matt
Calistri, +1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024